Biokinetic and Dosimetry of 90y-dotatoc Therapy for Neuroendocrine Tumours
نویسندگان
چکیده
Biokinetic model is a mathematical model which describes the behavior of the Y in human body during the treatment of neuroendocrine tumours. This paper presents calculation of absorbed doses in human organs in biokinetic model Y for DOTATOC therapy. For this purpose, the human body is represented by five compartments: blood, kidneys, urinary bladder, tumour and liver. The input file was developed and designed to calculate absorbed doses in human organs, when compartments, as kidneys, liver and tumour, are sources of Y. For this purpose, computer software MCNP5/X was used. To solve the system of equations obtained from the model, one data must be taken from the measurements of Y in blood or urine. Results obtained, showed that highest absorbed dose is in tumour, compared to other organs in human body.
منابع مشابه
Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
BACKGROUND The aim of this study was to assess the efficacy and safety of targeted radionuclide therapy with [90Y-DOTA0, Tyr3]-octreotide (90Y-DOTATOC) in patients with metastatic neuroendocrine tumors. PATIENTS AND METHODS One hundred and sixteen patients with metastatic neuroendocrine tumors were included. All patients were pre-therapeutically staged with morphological imaging procedures an...
متن کاملFeasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors
BACKGROUND Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient radiation dose to the tumor to result in a high percentage of long-term tumor remissions remains challenging because of the limits imposed on administered activity levels by radiation damage to normal tissues. The goa...
متن کاملRepeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of 131I-MIBG
131I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci) 131I-MIBG in a patient with metastatic paraganglioma. Ten courses of 131I-MIBG therapy were given within six years, accomplishing symptomatic, hormonal and tumour responses with no serious adverse...
متن کاملMultidisciplinary Symposium—neuroendocrine Tumours
Neuroendocrine tumours (NETs) are very rare diseases characterised by a high degree of histological and clinical heterogeneity. They can be silent (even producing some hormones) or clinically evident as a result of local growth and/or hormonal production. The diagnostic and therapeutic approach to patients with NETs should be multidisciplinary. A medical oncologist should coordinate a group of ...
متن کاملin metastasized gastrinoma
We aimed to explore the effects of 90Y-DOTATOC and 90Y-DOTATOC plus 177Lu-DOTATOC on survival of patients with metastasized gastrinoma. Patients with progressive metastasized gastrinoma were treated with repeated cycles of 90Y-DOTATOC or with cycles alternating between 90Y-DOTATOC and 177Lu-DOTATOC until tumor progression or permanent toxicity. Multivariable Cox regression analyses were used to...
متن کامل